|Bid||18.38 x 1400|
|Ask||18.38 x 1400|
|Day's Range||17.20 - 18.71|
|52 Week Range||6.54 - 49.51|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.00|
The consensus price target hints at a 288.6% upside potential for COMPASS Pathways PLC Sponsored ADR (CMPS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Again, my name is Steve Schultz, senior vice president of investor relations at COMPASS Pathways. The call is being recorded and will be available on the COMPASS Pathways' Investor Relations website shortly after the conclusion of the call.
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in anorexia nervosa launchedCash position at 30 June 2022 of $207.2 millionConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results